In overweight or obese patients with hidradenitis suppurativa receiving targeted biologics (e.g., TNF-α or IL-17 inhibitors), do you personally initiate GLP-1 receptor agonists for metabolic synergy, or do you defer prescribing to primary care?

Do you personally initiate GLP-1 receptor agonists for metabolic synergy, or do you defer prescribing to primary care for overweight or obese patients with HS who are already on biologics?

• I personally initiate GLP-1s in these patients
• I recommend GLP-1s but defer to PCP or other provider for prescription management
• I do not recommend GLP-1s for my HS patients
• Other